Quality System Approval Certificate
Medical Devices Directive 93/42/EEC

*The National Standards Authority of Ireland as a duly designated Notified Body, (identification number **0050**), for the purposes of the European Communities (Medical Devices) Regulations (S.I. No. 252 of 1994)*

APPROVES THE QUALITY SYSTEM APPLIED BY

Becton Dickinson and Company

1 Becton Drive
Franklin Lakes
NJ 07417
USA

to the Product Family

Hypodermic Syringes, insulin and general use (BD Micro-Fine™ +, BD Micro-Fine™ Plus, Micro-Fine™ IV, Ultra-Fine™ and Ultra-Fine™ II Insulin Syringes and Plastipak™ Allergy Syringes)

GMDN Code: 38501, 35904

on the basis of examination under the requirements of Directive 93/42/EEC on Medical Devices Annex V.
*The use of the NSAI Notified Body identification number **0050** in conjunction with CE Marking of Conformance for this product family is hereby authorised.*

Registration Number:	**252.140**
Original Approval:	**07 April 1995**
Last Amended on:	**15 April 2020**
Remains valid until:	**25 May 2024**

Signed:

Approved by:
Dr. Caroline Dore Geraghty
Director, Medical Devices

Approved by:
Dr. Elaine Darcy
European Medical Device Operations Manager

This certificate remains valid on condition that the Approved Quality System is maintained in an adequate and efficacious manner.
Details of the current product range and operational locations included within the scope of this approval can be obtained from NSAI
National Standards Authority of Ireland, 1 Swift Square, Northwood, Santry, Dublin 9, Ireland.

Becton Dickinson and Company
1 Becton Drive
Franklin Lakes
New Jersey
07417
USA

28 February 2024

Notified Body Confirmation Letter

Reference: EU2023-607/797149

To whom it may concern,

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices

This letter confirms that, **BSI Group The Netherlands B.V.**, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number **2797** on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

Becton Dickinson and Company
1 Becton Drive
Franklin Lakes
New Jersey
07417
USA

SRN Number: US-MF-000019182

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables below. Table 1 identifies the devices for which an MDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by the 20 Mar 2023 for the relevant devices.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- 31 December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of BSI Group The Netherlands B.V.,

Graeme Tunbridge
Senior Vice President, Medical Devices

Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
N/A	N/A	N/A	N/A

Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
BD Insulin Syringes 038290EZIEHWWZFB 038290FVPQYXYQQ9 038290UWLMWFQGS3	Class IIa	Not Applicable	MDD Certificate #252.140 NSAI 0050

Confirmation Letter Revision History

Date	Action
2024/02/28	Initial issue